Related Experiment Video
Updated: May 29, 2026
13:59
Assaying β-amyloid Toxicity using a Transgenic C. elegans Model
Published on: October 9, 2010
Coffee and amyotrophic lateral sclerosis: a possible preventive role
Ettore Beghi1, Elisabetta Pupillo, Paolo Messina
1Laboratory of Neurological Disorders, ‘‘Mario Negri’’ Institute, Via G. la Masa 19, 20156 Milano, Italy. ettore.beghi@marionegri.it
American Journal of Epidemiology
|September 28, 2011
Summary
Coffee consumption may reduce the risk of developing amyotrophic lateral sclerosis (ALS). This study found lower lifetime coffee intake in ALS patients compared to control groups, suggesting a protective effect of coffee.
Area of Science:
- Neurology
- Epidemiology
- Nutritional Science
Background:
- Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease with limited treatment options.
- Understanding modifiable risk factors, such as dietary habits, is crucial for prevention strategies.
Purpose of the Study:
- To investigate the association between coffee consumption and the risk of developing ALS.
- To determine if coffee intake influences the likelihood of ALS diagnosis.
Main Methods:
- A case-control study involving 377 newly diagnosed ALS patients and multiple control groups (hospital-based, general practitioner-based, and cancer cohort).
- Data collected on coffee consumption status, duration, and history (never, former, current).
- Statistical analysis using odds ratios (OR) with 95% confidence intervals (CI) to assess risk.
Main Results:
- ALS patients reported lower lifetime coffee consumption compared to all control groups.
- Ever coffee drinkers showed reduced ALS risk (ORs ranging from 0.4 to 0.7).
- Current coffee drinkers also exhibited a lower risk of ALS (ORs ranging from 0.4 to 0.7).
Conclusions:
- Findings suggest an inverse correlation between coffee intake and ALS risk.
- Coffee consumption may have a protective effect against the development of ALS.
- Further research is warranted to confirm these epidemiologic findings.
Related Concept Videos
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:24Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...